Overview of Dr. Hensley
Dr. Martee Hensley is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Duke University School of Medicine and has been in practice 28 years. Dr. Hensley accepts several types of health insurance, listed below. She is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 100 publications and over 500 citings.
Office
160 East 53rd Street
New York, NY 10022
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1992 - 1995
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1989 - 1992
- Duke University School of MedicineClass of 1989
Certifications & Licensure
- FL State Medical License 2021 - Present
- NY State Medical License 1990 - 2026
- NJ State Medical License 2019 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Start of enrollment: 2005 Jan 01
- Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2003 Dec 01
- Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Start of enrollment: 2006 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 335 citationsAmerican Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy ProtectantsMartee L. Hensley, Karen L. Hagerty, Tarun Kewalramani, Daniel M. Green, Neal J. Meropol
Journal of Clinical Oncology. 2009-01-01 - 871 citationsRisk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.Noah D. Kauff, Jaya M. Satagopan, Mark E. Robson, Lauren Scheuer, Martee L. Hensley
The New England Journal of Medicine. 2002-05-23 - 46 citationsPaclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.Mika A. Sovak, Martee L. Hensley, Jakob Dupont, Nicole Ishill, Kaled M. Alektiar
Gynecologic Oncology. 2006-11-01
Journal Articles
- Efficacy and Tolerability of Trabectedin in Elderly Patients with Sarcoma: Subgroup Analysis from a Phase 3, Randomized Controlled Study of Trabectedin or Dacarbazine ...A Elias, M Milhem, S Patel, S M Schuetze, M L Hensley, Annals of Oncology
Other
- Treatment and prognosis of uterine leiomyosarcomaHensley ML, Abu-Rustum NR
http://www.uptodate.com/contents/treatment-and-prognosis-of-uterine-leiomyosarcoma
UpToDate, Wolters Kluwer Health - 2013-04-11
Press Mentions
- Why the Health of Your Doctor MattersAugust 5th, 2019
- Expert Highlights Genetic Testing, Immunotherapy in Endometrial CancerJanuary 11th, 2018
- Trabectedin Offers Third-Line Option in Uterine LeiomyosarcomaMarch 24th, 2016
- Join now to see all
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois BlueChoice Select
BCBS Illinois PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPOGHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: